The ROVO Study: Radial Optic Neurotomy for CVO


The ROVO study is a prospective, placebocontrolled and randomised study designed to evaluate the effect of radial optic neurotomy in central vein occlusion, versus triamcinolone acetonide. 240 patients with a visual acuity < 0.5 Snellen will be randomised. Patients are treated with either RON, or a single intravitreal injection of 4 mg triamcinolone acetonide, or a placebo treatment – a "sham" injection of intravitreal triamcinolone. Patients will be examined regularly over a period of one year. Best corrected visual acuity for far and near, as well as clinical examinations, fluorescein- and indocyanine green angiograms, optical coherence tomography, and perimetry, are performed pre- and postoperatively.

Full Title of Study: “A Multicenter Trial for Surgical Treatment of Central Retinal Vein Occlusion – Radial Optic Neurotomy for CVO The ROVO Study”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Participant)


  • Drug: Intravitreal Triamcinolone
  • Procedure: Radial Optic Neurotomy
  • Other: Placebo – Sham Intravitreal Injection

Clinical Trial Outcome Measures

Primary Measures

  • Proportion of eyes with an improvement of more than 15 letters (approximately > 3 lines of visual acuity gain) after one year as compared to baseline

Participating in This Clinical Trial

Inclusion Criteria

  • Onset of CVO not longer than 12 months – On FLA 1. nonperfused – (greater than 10 disc area of nonperfusion) 2. perfused - visual acuity lower than 0.1 Snellen,or 3. perfused with no improvement of visual acuity over 4 weeks) Exclusion Criteria:

  • • Dense cataract* (grade 3 and 4) which precludes judgement of the fundus. – Pregnancy – Allergy against Fluoresceine or Indocyanine green – Unable to come for follow up visit – Presence of other severe retinopathy or – Presence of advanced optic atrophy or uncontrolled glaucoma. – Visual acuity higher than 0.5 Snellen.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Investigator Details

  • Lead Sponsor
    • Rudolf Foundation Clinic
  • Overall Official(s)
    • Susanne Binder, M.D., Study Chair, no affiliation

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.